Suppr超能文献

达沙替尼在费城染色体阴性白血病和骨髓疾病中的临床前及临床经验。

Preclinical and clinical experience with dasatinib in Philadelphia chromosome-negative leukemias and myeloid disorders.

作者信息

Verstovsek Srdan

机构信息

Leukemia Department, M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 428, Houston, TX 77030, USA.

出版信息

Leuk Res. 2009 May;33(5):617-23. doi: 10.1016/j.leukres.2008.10.001. Epub 2008 Nov 14.

DOI:10.1016/j.leukres.2008.10.001
PMID:19013641
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4428150/
Abstract

Recent advances in the molecular characterization of Philadelphia chromosome-negative (Ph-) leukemias and related myeloid disorders have provided a clear rationale for investigating novel targeted therapies. Dasatinib is a tyrosine kinase inhibitor with activity against BCR-ABL, platelet-derived growth factor receptors (PDGFRs), c- KIT, fibroblast growth factor receptors (FGFRs), SRC family kinases (SFKs), and EPHA receptors, all of which have been implicated in the pathogenesis of Ph- leukemias and myeloid disorders. This review presents emerging data on the preclinical and clinical activity of dasatinib in these diseases, which suggest that larger clinical studies are warranted.

摘要

费城染色体阴性（Ph-）白血病及相关髓系疾病分子特征的最新进展为研究新型靶向治疗提供了明确的理论依据。达沙替尼是一种酪氨酸激酶抑制剂，对BCR-ABL、血小板衍生生长因子受体（PDGFRs）、c-KIT、成纤维细胞生长因子受体（FGFRs）、SRC家族激酶（SFKs）和EPHA受体具有活性，所有这些都与Ph-白血病和髓系疾病的发病机制有关。本综述介绍了达沙替尼在这些疾病中的临床前和临床活性的新数据，表明有必要进行更大规模的临床研究。

相似文献

1
Preclinical and clinical experience with dasatinib in Philadelphia chromosome-negative leukemias and myeloid disorders.
Leuk Res. 2009 May;33(5):617-23. doi: 10.1016/j.leukres.2008.10.001. Epub 2008 Nov 14.
2
Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis.
Clin Cancer Res. 2008 Jun 15;14(12):3906-15. doi: 10.1158/1078-0432.CCR-08-0366.
3
Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Clin Ther. 2007 Nov;29(11):2289-308. doi: 10.1016/j.clinthera.2007.11.005.
4
Novel chromosomal aberration in Philadelphia negative cells of a patient with chronic myelogenous leukemia treated with dasatinib.
Leuk Lymphoma. 2008 May;49(5):1012-3. doi: 10.1080/10428190801975543.
5
Clonal hematopoiesis in Philadelphia chromosome-negative bone marrow cells of chronic myeloid leukemia patients receiving dasatinib.
Leuk Res. 2010 Jun;34(6):708-13. doi: 10.1016/j.leukres.2009.08.032. Epub 2009 Oct 4.
6
Dasatinib: an anti-tumour agent via Src inhibition.
Curr Drug Targets. 2011 Apr;12(4):563-78. doi: 10.2174/138945011794751591.
7
Dasatinib.
Recent Results Cancer Res. 2014;201:27-65. doi: 10.1007/978-3-642-54490-3_2.
8
Dasatinib for the treatment of Philadelphia chromosome-positive leukemias.
Expert Opin Pharmacother. 2012 Nov;13(16):2381-95. doi: 10.1517/14656566.2012.725722. Epub 2012 Sep 20.
9
Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.
Cancer. 2004 May 15;100(10):2064-78. doi: 10.1002/cncr.20211.
10
The potential for dasatinib in treating chronic lymphocytic leukemia, acute myeloid leukemia, and myeloproliferative neoplasms.
Leuk Lymphoma. 2011 May;52(5):754-63. doi: 10.3109/10428194.2011.555890. Epub 2011 Apr 4.

引用本文的文献

1
Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities.
Onco Targets Ther. 2018 Sep 25;11:6227-6237. doi: 10.2147/OTT.S170138. eCollection 2018.
2
Evidence for the persistence of an active endogenous retrovirus (ERVE) in humans.
Genetica. 2014 Oct;142(5):451-60. doi: 10.1007/s10709-014-9789-y. Epub 2014 Sep 6.

本文引用的文献

1
Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia.
Clin Cancer Res. 2011 May 1;17(9):2977-86. doi: 10.1158/1078-0432.CCR-10-2879. Epub 2011 Mar 14.
2
Dasatinib inhibits progenitor cell proliferation from polycythaemia vera.
Eur J Clin Invest. 2008 Aug;38(8):578-84. doi: 10.1111/j.1365-2362.2008.01982.x.
3
Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha.
Exp Hematol. 2008 Oct;36(10):1244-53. doi: 10.1016/j.exphem.2008.04.017. Epub 2008 Jul 10.
4
Molecular characterization of acute myeloid leukemia.
Haematologica. 2008 Jul;93(7):976-82. doi: 10.3324/haematol.13345.
5
Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis.
Clin Cancer Res. 2008 Jun 15;14(12):3906-15. doi: 10.1158/1078-0432.CCR-08-0366.
6
The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes.
Blood. 2008 Aug 15;112(4):1443-52. doi: 10.1182/blood-2007-11-123984. Epub 2008 Jun 12.
7
Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy.
Am J Hematol. 2008 Jun;83(6):491-7. doi: 10.1002/ajh.21183.
8
Eosinophilia with FIP1L1-PDGFRA fusion in a patient with chronic myelomonocytic leukemia.
J Clin Oncol. 2008 Apr 20;26(12):2040-1. doi: 10.1200/JCO.2007.15.3841.
9
Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies.
Leukemia. 2008 Jun;22(6):1117-24. doi: 10.1038/leu.2008.80. Epub 2008 Apr 10.
10
Acute lymphoblastic leukaemia.
Lancet. 2008 Mar 22;371(9617):1030-43. doi: 10.1016/S0140-6736(08)60457-2.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验